Search

Young EHA Committee

Welcome to the family! Get to know the Young EHA Committee and learn how you can make a difference. Join Young EHA through a junior membership.

EHA-NSHBT Sickle Cell Disease Webinar

EHA and the Topics-in-Focus Taskforce on Hemoglobinopathies are working with the Nigerian Society of Haematology and Blood Transfusion (NSHBT) to organize a webinar on Sickle Cell Disease (SCD).

7th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.

EHA launches Global Hematology Professionals’ Survey – make your voice heard

Mar 27 2023 Posted in Press releases

The Hague (Netherlands), March 27, 2023.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Program

All session times are in Eastern European Time (EET).

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.